PDL BioPharma, Inc. EV/FCF

EV/FCF of PDLI for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/FCF growth rates and interactive chart. A valuation metric that measures the enterprise value of a stock compared to its free cash flow. Free cash flow is calculated as operating cash flow - capital expenditures and is a more accurate measure of a company's earning power than net income, as it's not easily manipulated. A low EV/FCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/FCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.


Highlights and Quick Summary

Current EV/FCF of PDL BioPharma, Inc. is 3.46 (as of December 30, 2019)
  • EV/FCF for the quarter ending June 29, 2020 was -32.17 (a -1296.09% decrease compared to previous quarter)
  • Year-over-year quarterly EV/FCF decreased by -2673.81%
  • Annual EV/FCF for 2019 was 3.46 (a 65.36% increase from previous year)
  • Annual EV/FCF for 2018 was 2.09 (a 880.65% increase from previous year)
  • Annual EV/FCF for 2017 was 0.21 (a -93.11% decrease from previous year)
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/FCF of PDL BioPharma, Inc.

Most recent EV/FCFof PDLI including historical data for past 10 years.

Interactive Chart of EV/FCF of PDL BioPharma, Inc.

PDL BioPharma, Inc. EV/FCF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -32.17 2.69
2019 3.46 1.25 2.51 2.82 3.46
2018 2.09 1.39 0.92 1.97 2.09
2017 0.21 0.66 0.65 1.04 0.21
2016 3.1 3.33 2.65 1.81 3.1
2015 2.55 5.85 3.56 3.41 2.55
2014 3.83 10.86 35.12 17.69 3.83
2013 4.55 3.56 3.79 4.57 4.55
2012 5.29 6.01 4.96 5.07 5.29
2011 5.7 5.79 6.42 6.19 5.7
2010 0.0 0.0 0.0 0.0

Business Profile of PDL BioPharma, Inc.

Sector: Other
Industry: Other
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.